Abstract:Bruton's Tyrosine Kinase (BTK), a soluble tyrosine kinase plays an essential role in the growth, development, and signalling of B cells. It is a non-receptor kinase that is crucial for leukemic cell survival, proliferation, and oncogenic signalling in many B cell malignancies. The enhanced metastasis caused by BTK expression may be reduced by BTK inhibitors, which also have powerful therapeutic effects. The goal of the study is to identify potential inhibitors which have good binding affinity with BTK. The current study also aims to investigate the expression pattern and the prognostic significance of BTK across all cancer types. Interestingly, it was found that BTK was highly overexpressed in numerous cancer types including; clear cell renal carcinoma, glioblastoma, head and neck, liver and breast cancer. BTK was found to reduce the relapse-free and overall survival rate. Furthermore, using in silico approach two structural analogues of Pirtobrutinib namely; 163207918 and 129269825 that bind to BTK with higher affinity were identified. Using drug-likeness analysis the therapeutic possibility of screened Pirtobrutinib analogues were evaluated. The Molecular docking and dynamic analysis revealed that the new Pirtobrutinib analogues could be potent inhibitors with higher binding affinity and stability in comparison with the parent compound. In conclusion, after preclinical and clinical research, the identified analogues may open the door for their prospective use in cancer therapy.

A Structure‐Activity Investigation of the Fungal Metabolite (‐)‐TAN‐2483B: Inhibition of Bruton's tyrosine kinase.

Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Structure-based Discovery of Novel 4,5,6-Trisubstituted Pyrimidines As Potent Covalent Bruton’s Tyrosine Kinase Inhibitors

Design, Synthesis and Evaluation of Novel 5-Phenylpyridin-2(1h)-one Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors.

Biological Evaluation and Structure Modification of (S)-3-aminopyrrolidine Derivatives

Novel 6-Amino-1,3,5-triazine Derivatives As Potent BTK Inhibitors: Structure-Activity Relationship (SAR) Analysis and Preliminary Mechanism Investigation.

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a Pyrrolo[2,3-D]pyrimidine Scaffold

Expression analysis, molecular docking and molecular dynamics simulations to identify potential BTK inhibitors: strategy for targeting pan-cancer

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity

Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-Beta Type I Receptor Kinase Domain.

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines As Novel Bruton’s Tyrosine Kinase Inhibitors

Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents

Design, Synthesis and Biological Evaluation of Novel 2-Phenyl Pyrimidine Derivatives As Potent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Discovery and Structure-Activity Relationship of Novel Diphenylthiazole Derivatives As BTK Inhibitor with Potent Activity Against B Cell Lymphoma Cell Lines.

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase